TME Pharma

Dr. Maurizio PetitBon (chair)

Senior Advisor, BlackRock


Dr. PetitBon is Senior Advisor to BlackRock. He was general partner and co-founder of private debt provider Kreos Capital where he focused on healthcare investments until BlackRock acquired Kreos Capital. Prior to co-founding Kreos, Maurizio held senior positions in consulting at PMA Europe in London and Milano and at SRI International, in Menlo Park, California and London where he advised a number of U.S., European and Japanese technology companies and Private Equity funds on business development and M&A strategies. He also held a number of managerial positions at Emerson Electric, Digital Equipment and Xerox. Dr. PetitBon holds a doctor’s degree in mechanical engineering from the University of Rome and an MBA from INSEAD in Fontainebleau, France.

Susan Coles (deputy chair)

General Counsel and Head of Finance, Vivet Therapeutics 


Susan Coles is a specialist in corporate law with over 25 years of experience in international collaborations and corporate/commercial activities, including more than 20 years in the life sciences sector. Susan is General Counsel and Head of Finance at Vivet Therapeutics, a private gene therapy biotech company with a strong investor base, including Roche Venture Fund, Novartis Venture Funds, HealthCap, Columbus Venture Partners, Kurma Partners, Ysios Capital, Idinvest Partners and Pfizer Inc.
Prior to joining Vivet Therapeutics, Susan was General Counsel for 3 years at Stallergenes, a global leader in allergy immunotherapy, and also acted as General Counsel for 4 years at Inventiva, a clinical-stage biopharmaceutical company listed on Euronext and Nasdaq.
Between 2002-2012, Susan was Senior Counsel in charge of Licensing and Acquisitions at Laboratoires Fournier and subsequently at Solvay Pharmaceuticals, after its acquisition of Laboratoires Fournier.
Prior to these experiences, Susan worked for over 7 years in the field of international partnerships and mergers and acquisitions. Susan has a strong track record in advising senior management on strategic and operational matters as well as broad experience in business negotiation and strategic transactions. She holds a B.A. in Psychology from the University of British Columbia, and an LLB from the University of Toronto. Susan is an attorney of the Bar of Ontario and the New York Bar.

Dr. C. A. (Oscar) Izeboud

CEO, Scenic Biotech 


Dr. C. A. (Oscar) Izeboud is CEO of Scenic Biotech, a drug discovery and development company focused on genetic modifiers, based in the Netherlands. Before joining Scenic Biotech, Dr. Izeboud was Managing Director at NIBC Bank N.V. in Amsterdam, where he headed a life sciences and healthcare team and led corporate finance and capital markets activities with a focus on innovative companies. Prior to that, as Managing Director at Kempen & Co., a Dutch investment bank, he built the Life Sciences and Healthcare franchise and played a pivotal role in numerous international transactions in biotech, medtech, and the healthcare industry. Before his transition to the banking sector, Dr. Izeboud’s initial interest was in the biotech industry where he spent a number of years working for Crucell NV, Specs BV, and TNO Pharma.
Dr. Izeboud has been a nonexecutive member of the board of directors of Luciole Medical AG since 2019, and a member of the board of Nomad Bioscience GmbH since 2020. He holds a Ph.D. in immunopharmacology from the University of Utrecht in the Netherlands.


We use cookies

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (Google Analytics cookies). You can decide for yourself whether you want to accept the cookies. Please note that if you refuse cookies, you may no longer be able to use all of the site's functions.